These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

139 related articles for article (PubMed ID: 27071526)

  • 1. Challenges and opportunities of using liquid chromatography and mass spectrometry methods to develop complex vaccine antigens as pharmaceutical dosage forms.
    Hickey JM; Sahni N; Toth RT; Kumru OS; Joshi SB; Middaugh CR; Volkin DB
    J Chromatogr B Analyt Technol Biomed Life Sci; 2016 Oct; 1032():23-38. PubMed ID: 27071526
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Vaccine instability in the cold chain: mechanisms, analysis and formulation strategies.
    Kumru OS; Joshi SB; Smith DE; Middaugh CR; Prusik T; Volkin DB
    Biologicals; 2014 Sep; 42(5):237-59. PubMed ID: 24996452
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Formulation and stabilization of recombinant protein based virus-like particle vaccines.
    Jain NK; Sahni N; Kumru OS; Joshi SB; Volkin DB; Russell Middaugh C
    Adv Drug Deliv Rev; 2015 Oct; 93():42-55. PubMed ID: 25451136
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Analytical Characterization of an Oil-in-Water Adjuvant Emulsion.
    Sun J; Remmele RL; Sanyal G
    AAPS PharmSciTech; 2017 Jul; 18(5):1595-1604. PubMed ID: 27628187
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Characterization of a recombinant influenza vaccine candidate using complementary LC-MS methods.
    Xie H; Doneanu C; Chen W; Rininger J; Mazzeo JR
    Curr Pharm Biotechnol; 2011 Oct; 12(10):1568-79. PubMed ID: 21542793
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Simultaneous quantification of the viral antigens hemagglutinin and neuraminidase in influenza vaccines by LC-MSE.
    Creskey MC; Li C; Wang J; Girard M; Lorbetskie B; Gravel C; Farnsworth A; Li X; Smith DG; Cyr TD
    Vaccine; 2012 Jul; 30(32):4762-70. PubMed ID: 22643214
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Simultaneous quantification of hemagglutinin and neuraminidase of influenza virus using isotope dilution mass spectrometry.
    Williams TL; Pirkle JL; Barr JR
    Vaccine; 2012 Mar; 30(14):2475-82. PubMed ID: 22197963
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Label-free quantitative mass spectrometry for analysis of protein antigens in a meningococcal group B outer membrane vesicle vaccine.
    Dick LW; Mehl JT; Loughney JW; Mach A; Rustandi RR; Ha S; Zhang L; Przysiecki CT; Dieter L; Hoang VM
    Hum Vaccin Immunother; 2015; 11(6):1518-25. PubMed ID: 25997113
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Modern Vaccines/Adjuvants Formulation Session 6: Vaccine &Adjuvant Formulation & Production 15-17 May 2013, Lausanne, Switzerland.
    Fox CB
    Hum Vaccin Immunother; 2013 Sep; 9(9):2007-8. PubMed ID: 23787558
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Colocalized delivery of adjuvant and antigen using nanolipoprotein particles enhances the immune response to recombinant antigens.
    Fischer NO; Rasley A; Corzett M; Hwang MH; Hoeprich PD; Blanchette CD
    J Am Chem Soc; 2013 Feb; 135(6):2044-7. PubMed ID: 23331082
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Physicochemical and functional characterization of vaccine antigens and adjuvants.
    Dey AK; Malyala P; Singh M
    Expert Rev Vaccines; 2014 May; 13(5):671-85. PubMed ID: 24702271
    [TBL] [Abstract][Full Text] [Related]  

  • 12. State-of-the-art in liquid chromatography-mass spectrometry.
    Niessen WM
    J Chromatogr A; 1999 Sep; 856(1-2):179-97. PubMed ID: 10526788
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Innovative vaccine production technologies: the evolution and value of vaccine production technologies.
    Bae K; Choi J; Jang Y; Ahn S; Hur B
    Arch Pharm Res; 2009 Apr; 32(4):465-80. PubMed ID: 19407962
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Freeze-thaw stress of Alhydrogel ® alone is sufficient to reduce the immunogenicity of a recombinant hepatitis B vaccine containing native antigen.
    Clapp T; Munks MW; Trivedi R; Kompella UB; Braun LJ
    Vaccine; 2014 Jun; 32(30):3765-71. PubMed ID: 24856785
    [TBL] [Abstract][Full Text] [Related]  

  • 15. 2D-LC/MS techniques for the identification of proteins in highly complex mixtures.
    Nägele E; Vollmer M; Hörth P; Vad C
    Expert Rev Proteomics; 2004 Jun; 1(1):37-46. PubMed ID: 15966797
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Formulation development of a plant-derived H1N1 influenza vaccine containing purified recombinant hemagglutinin antigen.
    Iyer V; Liyanage MR; Shoji Y; Chichester JA; Jones RM; Yusibov V; Joshi SB; Middaugh CR
    Hum Vaccin Immunother; 2012 Apr; 8(4):453-64. PubMed ID: 22370514
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Mechanism of a decrease in potency for the recombinant influenza A virus hemagglutinin H3 antigen during storage.
    Hickey JM; Holtz KM; Manikwar P; Joshi SB; McPherson CE; Buckland B; Srivastava IK; Middaugh CR; Volkin DB
    J Pharm Sci; 2014 Mar; 103(3):821-7. PubMed ID: 24425059
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Administration of Poly[di(sodium carboxylatoethylphenoxy)phosphazene] (PCEP) and Avian Beta Defensin as Adjuvants in Inactivated Inclusion Body Hepatitis Virus and its Hexon Protein-Based Experimental Vaccine Formulations in Chickens.
    Dar A; Tipu M; Townsend H; Potter A; Gerdts V; Tikoo S
    Avian Dis; 2015 Dec; 59(4):518-24. PubMed ID: 26629626
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Vaccine technologies: From whole organisms to rationally designed protein assemblies.
    Karch CP; Burkhard P
    Biochem Pharmacol; 2016 Nov; 120():1-14. PubMed ID: 27157411
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Identification of pharmaceutical impurities in formulated dosage forms.
    Pan C; Liu F; Motto M
    J Pharm Sci; 2011 Apr; 100(4):1228-59. PubMed ID: 24081463
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.